Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management [Accessibility Statement] Skip NavigationAs oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-w ...